Arcturus Therapeutics
ARCT
31 hedge funds and large institutions have $60.3M invested in Arcturus Therapeutics in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
29% more funds holding
Funds holding: 24 → 31 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less capital invested
Capital invested by funds: $60.5M → $60.3M (-$274K)
29% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $2.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$2.26M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.3M |
| 3 |
Morgan Stanley
New York
|
+$1.13M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.03M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$678K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$3.44M |
| 2 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$1.56M |
| 3 |
SIM
Spark Investment Management
New York
|
-$487K |
| 4 |
EEG
E.E. Geduld
|
-$172K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$94.8K |
ARCT Hedge Fund Activity: Q2 2014 in Review
31 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2014, worth a combined $60.3M — down 0.45% from $60.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ARCT positions and 3 closed out — a net gain of 7 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $2.26M. The largest seller was Verition Fund Management, cutting an estimated $3.44M.
- 31 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2014, up from 24 in Q1 2014.
- Funds reported $60.3M of Arcturus Therapeutics stock for Q2 2014, down 0.45% quarter-over-quarter.
- 10 funds opened new Arcturus Therapeutics positions in Q2 2014 and 3 closed out, a net change of +7 holders.
- The largest Arcturus Therapeutics buyer in Q2 2014 was J. Goldman & Co, an estimated $2.26M added.
- The largest Arcturus Therapeutics seller in Q2 2014 was Verition Fund Management, an estimated $3.44M sold.
Based on aggregated 13F filings for Q2 2014.